-

Cosette Pharmaceuticals Appoints Brad Leonard as Vice President, Generics Commercial Operation

Experienced commercial leader joins Cosette to drive the next phase of growth and transformation

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. In this role, Brad will spearhead Cosette’s generics business, including Generics Sales, Marketing/Pricing, Customer Service, and Demand Planning, as the company continues its expansion in these markets.

“Cosette is in the midst of an exciting period of accelerated growth and portfolio expansion, and Brad is the right commercial leader to take our business to the next level,” said Apurva Saraf, President and CEO, Cosette Pharmaceuticals. “Brad’s deep expertise in the pharmaceutical industry, combined with his track record of driving commercial success and fostering strategic partnerships, will be a catalyst for our continued momentum.”

Brad played a pivotal role in the growth and success of Upsher-Smith Laboratories, LLC using a customer-focused approach to enhance their financial performance and commercial presence - demonstrated by over eight HDMA Diana Awards for product excellence and overall company performance.

“I am honoured to join Cosette at this pivotal moment in its journey,” said Brad Leonard, Vice President, Generics Commercial Operations. “The company’s bold vision, entrepreneurial spirit, and relentless focus on innovation make this an incredibly exciting time to be part of the team. I look forward to collaborating with the talented individuals at Cosette to accelerate our commercial execution, expand our market reach, and set new standards of excellence for the customers and patients we serve.”

With 30+ years of experience in the pharmaceutical industry, Brad is an experienced pharmaceutical executive with a robust background in pharmaceutical access and patient delivery across both generic and branded markets, cultivating and sustaining strong customer relationships, developing award-winning commercialization teams, and consistently driving sales and profit growth.

Brad holds a B.S. in Business Administration & Management from the University of Minnesota.

About Cosette Pharmaceuticals:

Cosette Pharmaceuticals, Inc. (“Cosette”) is a US-based, fully integrated pharmaceutical company with a fast-growing portfolio of branded pharmaceuticals consisting of products in women’s health, cardiology and dermatology. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (NASDAQ: HLNE). For more information, please visit www.cosettepharma.com and follow us on LinkedIn.

Contacts

Business Development: bd@cosettepharma.com
Commercial: sales@cosettepharma.com

Cosette Pharmaceuticals, Inc.

Details
Headquarters: Bridgewater, New Jersey, USA
CEO: Apurva Saraf
Employees: 350
Organization: PRI

Release Versions

Contacts

Business Development: bd@cosettepharma.com
Commercial: sales@cosettepharma.com

Social Media Profiles
More News From Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of CIPRO® HC (ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension), with 180 days Competitive Generic Therapy (CGT) exclusivity

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Cosette’s Abbreviated New Drug Application (ANDA) for the first generic version of CIPRO® HC (ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension), with 180 days of Competitive Generic Therapy (CGT) exclusivity. Cosette has commenced commercial shipments, triggering the 180 days of market...

Termination of Proposed Acquisition of Mayne Pharma

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on Mayne Pharma Group Limited (Mayne Pharma, ASX: Ticker MYX) terminating the agreement between Cosette and Mayne Pharma under which Cosette was to acquire all the outstanding shares of Mayne Pharma (Scheme Implementation Deed). Cosette also notes the announcements from Mayne Pharma on 10 December 2025 and 11 Dece...

Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. In this critical role, Jeff will lead Cosette’s best-in-class quality and regulatory affairs organizations, maintaining the company’s rigorous quality standards and further establishing Cosette’s strong position as a respected and reliable supplier of high-quality medicines....
Back to Newsroom